Brett S Carver1, Joel Sheinfeld. 1. Department of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. carverb@mskcc.org
Abstract
INTRODUCTION: Testicular cancer is the most common cancer in men age 20-35 years and accounts for approximately 1% of all male malignancies. While the retroperitoneum is often the first and only site of metastatic disease, approximately 40% of patients presenting with metastatic disease will have disease involving extra-retroperitoneal sites. MATERIALS AND METHODS: A medline review was conducted to evaluate peer-reviewed articles reporting on the outcome of patients with germ cell tumors and extra-retroperitoneal metastases. RESULTS: Following chemotherapy, approximately 70% of patients will have residual masses in the retroperitoneum and several series demonstrate that approximately 50% of patients will harbor teratoma or viable GCT in the retroperitoneum. Additionally, up to 35% of patients will have radiographic evidence of extra-retroperitoneal (ERP) masses after chemotherapy. CONCLUSION: In this manuscript, we will review the current role of surgery for patients with post-chemotherapy residual ERP metastases.
INTRODUCTION:Testicular cancer is the most common cancer in men age 20-35 years and accounts for approximately 1% of all male malignancies. While the retroperitoneum is often the first and only site of metastatic disease, approximately 40% of patients presenting with metastatic disease will have disease involving extra-retroperitoneal sites. MATERIALS AND METHODS: A medline review was conducted to evaluate peer-reviewed articles reporting on the outcome of patients with germ cell tumors and extra-retroperitoneal metastases. RESULTS: Following chemotherapy, approximately 70% of patients will have residual masses in the retroperitoneum and several series demonstrate that approximately 50% of patients will harbor teratoma or viable GCT in the retroperitoneum. Additionally, up to 35% of patients will have radiographic evidence of extra-retroperitoneal (ERP) masses after chemotherapy. CONCLUSION: In this manuscript, we will review the current role of surgery for patients with post-chemotherapy residual ERP metastases.
Authors: K Fizazi; S Tjulandin; R Salvioni; J R Germà-Lluch; J Bouzy; D Ragan; C Bokemeyer; A Gerl; A Fléchon; J S de Bono; S Stenning; A Horwich; J Pont; P Albers; U De Giorgi; M Bower; A Bulanov; G Pizzocaro; J Aparicio; C R Nichols; C Théodore; J T Hartmann; H J Schmoll; S B Kaye; S Culine; J P Droz; C Mahé Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: C R Nichols; S D Williams; P J Loehrer; F A Greco; E D Crawford; J Weetlaufer; M E Miller; A Bartolucci; L Schacter; L H Einhorn Journal: J Clin Oncol Date: 1991-07 Impact factor: 44.544
Authors: S B Kaye; G M Mead; S Fossa; M Cullen; R deWit; I Bodrogi; C van Groeningen; R Sylvester; L Collette; S Stenning; L De Prijck; E Lallemand; P deMulder Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: N Aass; O Klepp; E Cavallin-Stahl; O Dahl; H Wicklund; B Unsgaard; L Baldetorp; S Ahlström; S D Fosså Journal: J Clin Oncol Date: 1991-05 Impact factor: 44.544
Authors: E P Fox; T D Weathers; S D Williams; P J Loehrer; T M Ulbright; J P Donohue; L H Einhorn Journal: J Clin Oncol Date: 1993-07 Impact factor: 44.544
Authors: E W Steyerberg; H J Keizer; S D Fosså; D T Sleijfer; G C Toner; H Schraffordt Koops; P F Mulders; J E Messemer; K Ney; J P Donohue Journal: J Clin Oncol Date: 1995-05 Impact factor: 44.544